GCs stimulators or GCs activators alone and in combination with PDE5 inhibitors for the treatment of cystic fibrosis

摘要

Use of a stimulator or activator of the GCs selected from the group comprising 2- [1- (2-fluorobenzyl) -1 Hpirazolo [3,4-b] pyridin-3-yl] -5- (4-morpholinyl) -4, 6-pyrimidinediamine (1), 2- [1- (2-fluorobenzyl) -1H-pyrazolo [3,4-b] pyridin-3-yl] -5- (4-pyridinyl) -4-pyrimidinamine (2), methyl-4,6-diamino-2- [1- (2-fluorobenzyl) -1 H -pyrazolo [3,4-b] pyridin-3-yl] -5-pyrimidinyl (methyl) carbamate (3), methyl-4 , 6-diamino-2- [1- (2-fluorobenzyl) -1 H -pyrazolo [3,4-b] pyridin-3-yl] -5-pyrimidinylcarbamate (4), 3- (4-amino-5-cyclopropylpyrimidin -2-yl) -1- (2-fluorbenzyl) 1H-pyrazolo [3,4-b] pyridine (4a), sodium salt of 5-chloro-2- (5-chlorothiophene-2-sulfonylamino-N- ( 4- (morpholine-4-sulfonyl) -phenyl) -benzamide (6), 2- (4-chlorophenylsulfonylamino) - 4,5-dimethoxy-N- (4- (thiomorpholine-4-sulfonyl) -phenyl) -benzamide ( 7) and / or 4 - ({(4-carboxybutyl) [2- (2- {[4- (2-phenylethyl) benzyl] oxy} phenyl) ethyl] amino} methyl) benzoic acid (5), 1- acid {6- [5-Chloro-2 - ({4-trans-4-} trifluoromethyl) cyclohexyl] benzyl} oxy) phenyl] pyridin-2-yl} -5- (trifluoromethyl) -1H-pyrazo l-4-carboxylic (8), 1- [6- (2- (2-methyl- 4- (4-trifluoromethoxyphenyl) benzyloxy) -phenyl) pyridin-2-yl] -5-trifluoromethyl-pyrazol-4- carboxylic (9), 1 [6- (3,4-dichlorophenyl) -2-pyridinyl-5- (trifluoromethyl) -1H-pyrazol-4-carboxylic acid (10), 1 - ({2- [3-chloro] -5- (trifluoromethyl) phenyl] -5-methyl-1,3-thiazol-4- yl} methyl) -1 H -pyrazol-4-carboxylic acid (11), 4 - ({2- [3- (trifluoromethyl) acid phenyl] -1,3-thiazol-4-yl} methyl) benzoic (12), 1 - ({2- [2-fluoro-3- (trifluoromethyl) phenyl] -5-methyl-1,3-thiazole- 4-yl} methyl) -1 H -pyrazol-4-carboxylic (13) for the manufacture of a medicament for the treatment of cystic fibrosis (CF).